These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36434612)

  • 1. Prognostic markers in patients with chronic lymphocytic leukaemia on targeted therapy, chemoimmunotherapy with anti-CD20 monoclonal antibody: a systematic review and meta-analysis of prognostic factors.
    Mkhwanazi ZA; Nyambuya TM; Mfusi SA; Nkambule BB
    BMC Cancer; 2022 Nov; 22(1):1218. PubMed ID: 36434612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance therapy for chronic lymphocytic leukaemia.
    Lee CH; Wu YY; Huang TC; Lin C; Zou YF; Cheng JC; Chen PH; Jhou HJ; Ho CL
    Cochrane Database Syst Rev; 2024 Jan; 1(1):CD013474. PubMed ID: 38174814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Plus Anti-CD20 Antibody Therapy Compared With Chemoimmunotherapy as Front-line Treatment for Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Nguyen TT; Thanh Nhu N; Tran VK; Van Cau N; Lin CF
    J Immunother; 2023 Oct; 46(8):299-309. PubMed ID: 37216406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations.
    Soumerai JD; Ni A; Darif M; Londhe A; Xing G; Mun Y; Kay NE; Shanafelt TD; Rabe KG; Byrd JC; Chanan-Khan AA; Furman RR; Hillmen P; Jones J; Seymour JF; Sharman JP; Ferrante L; Mobasher M; Stark T; Reddy V; Dreiling LK; Bhargava P; Howes A; James DF; Zelenetz AD
    Lancet Haematol; 2019 Jul; 6(7):e366-e374. PubMed ID: 31109827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis.
    Kreuzberger N; Damen JA; Trivella M; Estcourt LJ; Aldin A; Umlauff L; Vazquez-Montes MD; Wolff R; Moons KG; Monsef I; Foroutan F; Kreuzer KA; Skoetz N
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012022. PubMed ID: 32735048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia.
    Jain P; O'Brien S
    Expert Opin Biol Ther; 2013 Feb; 13(2):169-82. PubMed ID: 23256681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of genetic abnormalities in 536 first-line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV-mutated subgroups (a FILO study).
    Nguyen-Khac F; Baron M; Guièze R; Feugier P; Fayault A; Raynaud S; Troussard X; Droin N; Damm F; Smagghe L; Susin S; Leblond V; Dartigeas C; Van den Neste E; Leprêtre S; Bernard OA; Roos-Weil D;
    Br J Haematol; 2024 Aug; 205(2):495-502. PubMed ID: 38654616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Markers in the Era of Targeted Therapies.
    Kang S; Ahn IE
    Acta Haematol; 2024; 147(1):33-46. PubMed ID: 37703841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
    Langerbeins P; Giza A; Robrecht S; Cramer P; von Tresckow J; Al-Sawaf O; Fink AM; Fürstenau M; Kutsch N; Simon F; Goede V; Hoechstetter M; Niemann CU; da Cunha-Bang C; Kater A; Dubois J; Gregor M; Staber PB; Tausch E; Schneider C; Stilgenbauer S; Eichhorst B; Fischer K; Hallek M
    Blood; 2024 Jun; 143(25):2588-2598. PubMed ID: 38620092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
    Byrd JC; Gribben JG; Peterson BL; Grever MR; Lozanski G; Lucas DM; Lampson B; Larson RA; Caligiuri MA; Heerema NA
    J Clin Oncol; 2006 Jan; 24(3):437-43. PubMed ID: 16344317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
    Shanafelt T; Lanasa MC; Call TG; Beaven AW; Leis JF; LaPlant B; Bowen D; Conte M; Jelinek DF; Hanson CA; Kay NE; Zent CS
    Cancer; 2013 Nov; 119(21):3788-96. PubMed ID: 23922059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Mistry H; Nduka C; Connock M; Colquitt J; Mantopoulos T; Loveman E; Walewska R; Mason J
    Pharmacoeconomics; 2018 Apr; 36(4):399-406. PubMed ID: 29222670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment.
    Hallek M
    Am J Hematol; 2017 Sep; 92(9):946-965. PubMed ID: 28782884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
    Fink AM; Bahlo J; Robrecht S; Al-Sawaf O; Aldaoud A; Hebart H; Jentsch-Ullrich K; Dörfel S; Fischer K; Wendtner CM; Nösslinger T; Ghia P; Bosch F; Kater AP; Döhner H; Kneba M; Kreuzer KA; Tausch E; Stilgenbauer S; Ritgen M; Böttcher S; Eichhorst B; Hallek M
    Lancet Haematol; 2017 Oct; 4(10):e475-e486. PubMed ID: 28916311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
    Cramer P; von Tresckow J; Eichhorst B; Hallek M
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab for patients with chronic lymphocytic leukaemia.
    Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A
    Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving treatment for patients with chronic lymphocytic leukemia.
    Shanafelt TD
    Hematology; 2012 Apr; 17 Suppl 1():S133-6. PubMed ID: 22507801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of antibody therapy in chronic lymphocytic leukemia.
    Crombie JL; Brown JR
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):323-336. PubMed ID: 34375544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.